LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell ...

Encapsulating human stem-cell-derived beta cells in microcapsules made with an immune-cell-repelling protein restored glucose metabolism in diabetic mice and protected the cells from immune system ...

Technological advancements can address the formulation and dissolution challenges of HPMC polymers. Editor’s Note: A version of this article was published in Pharmaceutical Technology Europe’s APIs, ...

Homogeneous molecular catalysts are highly active and selective as they possess well-tailored structures and accessible sites. Unfortunately, the difficulty related to catalyst recovery impedes their ...

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, said, “We have completed another study that proves exactly what we expected to find in the data. Like previous biocompatibility studies on ...